Related Experiment Videos
Multidisciplinary care in cancer: do the current research outputs help?
M Carey1, R Sanson-Fisher, K Lotfi-Jam
1Centre for Behavioural Research in Cancer, The Cancer Council Victoria, Carlton, Vic., Australia. Mariko.Carey@cancervic.org.au
European Journal of Cancer Care
|January 29, 2010
Summary
Despite increased focus on multidisciplinary care (MDC) for cancer patients, rigorous intervention research has not grown. More high-quality studies are needed to determine the most effective MDC models for cancer care.
Area of Science:
- Oncology
- Health Services Research
- Evidence-Based Practice
Background:
- Multidisciplinary care (MDC) is increasingly advocated for cancer patients.
- There is a need to assess if research supporting MDC has improved in quality and quantity.
- Previous research has not systematically evaluated the methodological rigor of intervention studies in this field.
Purpose of the Study:
- To determine if methodologically rigorous intervention research in multidisciplinary cancer care has increased over the last decade.
- To evaluate the proportion of data-based and intervention research meeting specific quality criteria (Cochrane EPOC) over two time periods.
- To identify the extent of high-quality intervention research supporting the implementation of multidisciplinary care models in oncology.
Main Methods:
- Conducted an electronic search of Medline and CINAHL databases for relevant literature.
- Included studies published in English between 1997 and 2006, focusing on multidisciplinary care for cancer patients.
- Assessed papers for data-based research and intervention studies meeting Cochrane Effective Practice and Organisation of Care (EPOC) criteria.
Main Results:
- The proportion of data-based papers relevant to multidisciplinary cancer care did not increase between 1997-2001 and 2002-2006.
- Similarly, the proportion of intervention research using EPOC-accepted designs did not show an increase over the study periods.
- Only three intervention studies with EPOC-accepted designs were identified, all published in the later period (2002-2006).
Conclusions:
- Despite the widespread advocacy for multidisciplinary care (MDC) in cancer, there has not been a corresponding increase in rigorous intervention research.
- A significant gap exists in high-quality evidence to guide the optimal implementation of MDC models.
- There is a pressing need to prioritize and develop robust intervention research to identify effective MDC strategies, outcomes, and patient populations in cancer care.
Related Concept Videos
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...